Blood test identifies acute myeloid leukemia patients at greater risk for relapse after bone marrow transplant

Researchers at the National Institutes of Health show the benefits of screening adult patients in remission from acute myeloid leukemia (AML) for residual disease before receiving a bone marrow transplant. The findings, published in JAMA, support ongoing research aimed at developing precision medicine and personalized post-transplant care for these patients.

Leave A Comment

Your email address will not be published. Required fields are marked *